LEUKEMIAS

Hetty Carraway, MD, discusses the process of diagnosing acute myeloid leukemia and its clinical subtypes.

The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.

Courtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.

A review of the safety outcome data of venetoclax plus azacitidine from the VIALE-A trial.

Dr Courtney DiNardo details the dosing recommendations for venetoclax plus azacitidine and the importance of bone marrow assessments.

Dr Courtney DiNardo reviews the efficacy data from the VIALE-A trial and explains the rationale for combining venetoclax with azacitidine as a treatment option for patients with AML.

Courtney DiNardo, MD, describes how the treatment options for patients with newly diagnosed acute myeloid leukemia differs for patients under and over 60 years of age.

Quizartinib with standard induction and consolidation chemotherapy followed by continued quizartinib monotherapy treatment led to significant improvement in overall survival in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

The FDA has granted approval to azacitidine for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia following positive phase 2 research.

Hagop M. Kantarjian, MD, discusses the introduction of chimeric antigen receptor T cells and their impact on acute lymphoblastic leukemia.

Hagop M. Kantarjian, MD, discusses how the treatment landscape of acute lymphocytic leukemia compares to what it used to be.

Retrospective data signal that transplant with a matched sibling donor may prolong survival over haploidentical stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.

In an interview with Targeted Oncology, Eytan M. Stein, MD, hematologic oncologist from Memorial Sloan Kettering Cancer Center, discusses the latest treatment developments and updates within the AML space.

With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.

The UKALL14 misses the primary end point of improvement in event-free survival in patients with acute lymphoblastic leukemia.

The phase 1/2 TakeAim Leukemia study exploring emavusertib in patients with acute myeloid leukemia and myelodysplastic syndrome has been halted by the FDA pending more safety and efficacy data.

In an interview with Targeted Oncology, David Siegel, MD, explained the many changes seen in pediatric cancer mortality and survival over the past 40 years.

Marcin Kortylewski, PhD, discusses research demonstrating blocking STAT3 in acute myeloid leukemia (AML) cells.

SWOG 1318 results are promising for extended blinatumomab use in patients with acute lymphoblastic leukemia.

Acute myeloid leukemia has one of the highest unmet needs for new therapies out of all human cancers, according to Marcin Kortylewski.

Nitin Jain, MD, discusses the preliminary results of a study investigating allogeneic chimeric antigen receptor T-cell therapy with lymphodepletion in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

The National Comprehensive Cancer Network has updated its guidelines on ALL in adolescents and young adults.

Despite advances with MRD monitoring, further research and practice advances are needed to continue the trend for improving outcomes in patients with acute lymphoblastic leukemia.

Drs Shadman and Cohen review clinical trials of zanubrutinib in B-cell lymphomas.

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, talk about disease progression on BTKi and what mechanisms of resistance can occur.

The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Treatment with the investigational agent SY-2101 has begun in a phase 3 clinical trial of patients with newly-diagnosed acute promyelocytic leukemia.

An oncologist discusses the future of myelodysplastic syndrome, including upcoming studies and potential treatments.

Dr. Naval Daver provides insight on the emerging first-line treatment options for high-risk myelodysplastic syndrome and breaks down clinical trial data.